UK Delegation Explores International Collaboration and Growth in Dutch MedTech Market
CardioCrown was among eight UK-based MedTech and diagnostics companies selected to participate in the Global Business Innovation Programme (GBIP), a strategic initiative led by Innovate UK and delivered by Innovate UK EDGE. This programme supports UK businesses with ambitions to expand globally by providing access to new markets, innovation opportunities, and international networks. CardioCrown’s involvement marks a pivotal step towards expanding its market reach and forging partnerships within the Dutch medical technology landscape.
The programme includes a 5-day innovation visit, followed by an exploitation workshop and 12 months of continued support from Innovate UK EDGE’s Innovation and Growth Specialists. Through this initiative, UK businesses like CardioCrown can explore new market opportunities, understand the nuances of doing business in the Netherlands, and develop projects alongside potential international partners.
Victor Harbari, CEO of CardioCrown, shared: “The Global Business Innovation Programme provides an invaluable platform for us to engage with the MedTech ecosystem in the Netherlands. This experience has broadened our perspective on international collaboration, enabling us to better position CardioCrown for meaningful partnerships and sustained growth in new markets.”
Exploring the Dutch MedTech Landscape
Participating in this programme enabled CardioCrown and other UK companies to gain first-hand insights into the Dutch MedTech and diagnostics sectors. The programme’s benefits are extensive, from enhancing each company’s value proposition to discovering new partners and exploring challenges and opportunities unique to the Dutch market.
By fostering cross-border partnerships and facilitating innovative projects, the GBIP prepares UK businesses to successfully enter international markets, positioning them as competitive players on the global stage. For CardioCrown, this experience will play a significant role in its journey to drive global growth and impact through MedTech innovation.
